UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 9, 2006
Lifeline Therapeutics, Inc.
| Colorado | 000-30489 | 84-1097796 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
6400 South Fiddler’s Green Circle, Suite 1970, Englewood, CO 80111
Registrant’s telephone number, including area code: (720) 488-1711
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure
On February 9, 2006, Lifeline Therapeutics, Inc. issued a press release entitled “Lifeline
Therapeutics, Inc. Schedules Second Quarter Earnings Conference Call and Webcast.” The press
release is attached as Exhibit 99.1 hereto.
Item 9.01 Exhibits
99.1 Press Release, dated February 9, 2006, entitled “Lifeline Therapeutics, Inc. Schedules
Second Quarter Earnings Conference Call and Webcast.”
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
Date: February 9, 2006
| LIFELINE THERAPEUTICS, INC. |
||||
| By: | /s/ Gerald J. Houston | |||
| Gerald J. Houston | ||||
| Chief Financial Officer | ||||
EXHIBIT INDEX
| Exhibit No. | Description | |
99.1
|
Press Release, dated February 9, 2006, entitled “Lifeline Therapeutics, Inc. Schedules Second Quarter Earnings Conference Call and Webcast.” |
EXHIBIT 99.1
FOR IMMEDIATE RELEASE
|
NEWS | |
February 9, 2006
|
OTCBB: LFLT |
LIFELINE THERAPEUTICS, INC. SCHEDULES
SECOND QUARTER EARNINGS CONFERENCE CALL AND WEBCAST
SECOND QUARTER EARNINGS CONFERENCE CALL AND WEBCAST
DENVER, Colorado — Lifeline Therapeutics, Inc. (“Lifeline” or the “Company”) (OTCBB: LFLT), maker
of Protandim®, will hold a conference call on Monday, February 13, 2006 at 8:00 a.m. MST
(10:00 a.m. EST) to discuss its second quarter fiscal year 2006 financial and operating results.
Interested parties may listen to the call via webcast by accessing the link on Lifeline
Therapeutics’ website at www.lifelinetherapeutics.com or by calling 800-240-7305. A replay will be
available on the website until February 20, 2006. A replay of the call also will be available by
telephone until February 20, 2006 at 800-405-2236 passcode 11053378#.
About Lifeline Therapeutics
Lifeline Therapeutics, Inc. markets Protandim®, a patent-pending dietary supplement that increases
the body’s natural antioxidant protection. Lifeline Therapeutics is committed to helping people
achieve health and wellness ... for life. For more information, please visit the Protandim®
product website at http://www.protandim.com.
Oxidative stress (cell damage caused by free radicals) occurs as a person ages or is subjected to
stresses such as certain illnesses. TBARS are harmful, reactive substances that indicate the level
of oxidative stress in the body. New data from a scientific study in men and women show that after
30 days of taking Protandim®, the level of circulating TBARS decreased an average of 40 percent,
and the age-related increase in TBARS was eliminated. Protandim® strengthens a person’s defenses
against oxidative stress by increasing the body’s natural activity of antioxidant enzymes.
Except for historical information contained herein, this document contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995 and
applicable common law. These statements involve known and unknown risks and uncertainties that may
cause the Company’s actual results or outcomes to be materially different from those anticipated
and discussed herein. Further, the Company operates in industries where securities values may be
volatile and may be influenced by regulatory and other factors beyond the Company’s control. Other
important factors that the Company believes might cause such differences include the Company’s
limited cash flow and the rapid development of technology, lack of liquidity for the Company’s
common stock, working capital shortages, the length of time for scientific advances to reach the
market (if they ever reach the market), among other risks. In assessing forward-looking statements
contained herein, readers are urged to carefully read all cautionary statements contained in the
Company’s filings with the Securities and Exchange Commission.
CONTACT:
Lifeline Therapeutics Inc |
||||
Stephen K. Onody, CEO
|
Telephone: | 720-488-1711 | ||
Gerald J. Houston, CFO
|
Fax: | 303-565-8700 |